Supernus Pharmaceuticals reported $5.47M in Interest Expense on Debt for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbott ABT:US $ 123M 12M
Aerie Pharmaceuticals AERI:US $ 7.12M 0.22M
Ani Pharmaceuticals ANIP:US $ 2.53M 77K
Aphria Inc APH:CN C$ 10.45M 3.97M
Aurora Cannabis Inc ACB:CN 16.99M 1.88M
Bristol Myers Squibb BMY:US $ 330M 23M
Canopy Growth Corp WEED:CN C$ 24.56M 19.81M
Eli Lilly And LLY:US $ 86.9M 0.9M
Endo International Ordinary Shares ENDP:US $ 141.64M 6.95M
Gw Pharmaceuticals GWPH:US $ 0.29M 0.02M
JAZZ PHA JAZZ:US $ 69.82M 41.24M
Lannett LCI:US $ 13.22M 0.59M
Pacira Pharmaceuticals PCRX:US $ 7.02M 0.05M
Pfizer PFE:US $ 316M 20M
Revance Therapeutics RVNC:US $ 1.57M 9K
Supernus Pharmaceuticals SUPN:US $ 5.47M 0.4M
Teva Pharmaceutical Industries TEVA:US $ 240M 1M
United Therapeutics UTHR:US $ 4.7M 0.1M
Xeris Pharmaceuticals Inc XERS:US $ 1.8M 4K